odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
5919
10.69690/ODMJ-001-1230-5919
Original Research
Treatment Outcome of Childhood Hepatoblastoma: A Single Centre Experience in Bangladesh
https://orcid.org/0000-0002-2144-4837
Yasmin
Farida
Pediatric Hematology & Oncology Department, National Institute of Cancer Research and Hospital, Bangladesh
faridayasmin71@yahoo.com
Jamal
Chowdhury Yakub
Pediatric Hematology & Oncology Department, Bangladesh Medical University
Islam
Afiqul
Pediatric Hematology & Oncology Department, Bangladesh Medical University
Karim
Anwarul
Pediatric Hematology & Oncology Department, Bangladesh Medical University
Begum
Ferdousi
Pediatric Hematology & Oncology Department, National Institute of Cancer Research and Hospital, Bangladesh
Begum
Momnea
Pediatric Hematology & Oncology Department, Bangladesh Medical University
Ara
Zannat
Pediatric Hematology & Oncology Department, Dhaka Medical College and Hospital, Bangladesh
Molla
Lutfor Rahman
Pediatric Hematology & Oncology Department, Sylhet MAG Osmani Medical College and Hospital, Bangladesh
30
12
2025
ODMJ-001-1230-5919
Copyright (c) 2025 OncoDaily Medical Journal
2025
OncoDaily Medical Journal
Bangladesh
childhood hepatoblastoma
production-ready-file-url
[
Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology. 2003;38(3):560-6.
]
[
Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of paediatric hepatoblastoma: a report from the Children’s Cancer Group and the Paediatric Oncology Group. J Clin Oncol. 2000;18(14):2665-75.
]
[
Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach—results of the first prospective study of the International Society of Paediatric Oncology. J Clin Oncol. 2000;18(22):3819-28.
]
[
Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993;11(1):96-9.
]
[
Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. 2004;42(1):74-83.
]
[
Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol. 2002;20(12):2798-804.
]
[
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009;361(17):1662-70.
]
[
Rahman MA, Begum F, Karim S, Murtuza A, Islam A, et al. Multimodality treatment outcome of hepatoblastoma in a resource-limited country. Mymensingh Med J. 2017;26(2):272-8.
]
[
Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol. 2010;28(15):2584-90.
]
[
Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, Brock P, et al. Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology SIOPEL 2. Eur J Cancer. 2004;40(3):411-21.
]
[
Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
]
[
Dhali A, Mandal TS, Das S, et al. Clinical profile of hepatoblastoma: experience from a tertiary care centre in a resource-limited setting. Cureus. 2022;14(7):e26494.
]
[
Tian Z, Zhang WL, Zhang Y, Hu HM, Huang DS. Clinical characteristics and prognostic factors of hepatoblastoma in 316 children aged under 3 years: a 14-year retrospective single-center study. BMC Pediatr. 2021;21:170.
]
[
Ansell P, Michell CD, Roman E, Simpson J, Birch JM, Eden TOB. Relationship between perinatal and maternal characteristics and hepatoblastoma: a report from the UKCCS. Eur J Cancer. 2005;41(5):741-8.
]
[
Zsíros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013;14(9):834-40.
]
[
Malogolowkin MH, Howard M, Katzenstein H, Meyers ML, Krailo MD, Reynolds JM, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children’s Oncology Group. J Clin Oncol. 2011;29(24):3301-6.
]
[
Fuchs J, Rydzynski J, von Schweinitz D, Bode U, Hecker H, Weinel P, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer. 2002;95(1):172-82.
]
[
Manuprasad A, Radhakrishnan V, Sunil B, et al. Hepatoblastoma: 16-years’ experience from a tertiary cancer centre in India. Pediatr Hematol Oncol J. 2018;3:13-6.
]
[
Liu APY, Ip JJK, Leung AWK, et al. Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong. Pediatr Blood Cancer. 2019;66(1):e27482.
]
[
Shanmugam N, Scott JX, Kumar V, Vij M, Ramachandran P, Narasimhan G, et al. Multidisciplinary management of hepatoblastoma in children: experience from a developing country. Pediatr Blood Cancer. 2017;64(3):e26249.
]
[
Black CT, Cangir A, Choroszy M, Andrassy J. Marked response to preoperative high-dose cisplatinum in children with unresectable hepatoblastoma. J Pediatr Surg. 1991;26(9):1070-3.
]